Fulcrum Therapeutics (Nasdaq: FULC) announced Monday it has entered into a definitive agreement to merge with privately held Slate Medicines in an all-stock transaction. The combined company will operate under the Slate Medicines name and pivot entirely away from Fulcrum’s original rare hematological disease pipeline toward Slate’s portfolio of next-generation migraine therapeutics. Alongside the merger, the companies announced an oversubscribed $245 million private placement from a syndicate of healthcare investors, expected to fund the combined operations into 2029.